Kirkpatrick Lynn 4
4 · Ensysce Biosciences, Inc. · Filed Feb 24, 2022
Insider Transaction Report
Form 4
Kirkpatrick Lynn
DirectorChief Executive Officer
Transactions
- Award
Stock Option
2022-02-17+200,000→ 200,000 totalExercise: $1.40Exp: 2032-02-17→ Common Stock (200,000 underlying)
Footnotes (1)
- [F1]On February 17, 2022, Dr. Kirkpatrick was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter.